Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
about
P2Y12-ADP receptor antagonists: Days of future and pastState of the art: Oral antiplatelet therapyType 2 Diabetes and ADP Receptor Blocker TherapyShould dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trialsAdjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxarThe prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysisRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceRecent advances in treatment of acute coronary syndromesTreatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapyHigh-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisExpert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyThe risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease.Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary interventionEarly clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.Recent advances in antithrombotic therapy after acute coronary syndrome.Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison.Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyHealth economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysisImpact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome.Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Importance of frailty in patients with cardiovascular disease.Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes.Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.Causes of late mortality with dual antiplatelet therapy after coronary stents.Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a reviewState of the art in platelet function testing.Doubly blind: a systematic review of gender in randomised controlled trials.Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndromeSwitching between thienopyridines in patients with acute myocardial infarction and quality of care.Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetesOutcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital RevascularizationThe perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.New antiplatelet agents for cardiovascular disease.Bleeding events and maintenance dose of prasugrel: BLESS pilot study.
P2860
Q26745619-6549EA54-6C0C-40DF-B09E-FC048C9E8396Q26746161-B52D28F7-69EC-40EE-AAE1-DD8E3B742CEDQ26772996-59FCF99B-CAB6-480D-9682-B8792926214AQ26782970-BB5BDE32-254F-48FB-8473-423531CB44BDQ26801144-8CC7B64F-2F98-4CAC-B339-4B1D6E20DEA6Q26824694-A81C68EA-F385-49BE-8376-9FC1A446D47AQ26825230-EA94447A-5813-4476-8CAF-6AF3EA813B91Q26862897-00F933EC-59CB-499D-8038-D5D7EEEE874DQ26866350-B40D5140-2EA9-4B03-A5BC-8A1113D8CD56Q26996325-040D2E21-B6FA-495E-920C-9703E232E901Q26998331-05B4745C-1E26-49AB-9172-72A0DBDF7E95Q30234909-D03EA0C4-DF2A-493E-B3E5-B57F7D7BB275Q30371026-E37914BD-2DE0-4130-8A5E-F26D9319A938Q30800602-C4B73027-2A48-4B9F-9D11-BA9BA4F4AA28Q33590548-1115C170-C8C9-47CB-97BE-06DC97B17038Q33706621-ACDB8F9C-5D67-4129-852B-1F603A1D77C1Q34043989-E4833F3C-9995-4667-BC73-2C05998A0772Q34371979-87B4F2C1-8C16-49AB-B639-430041E20BF9Q34456208-92450A49-A0FC-4F02-8268-F6CCDF46D3C1Q35048557-6AD5DE36-0C7B-4CC0-B684-5C3652A5767BQ35089550-B95FE59F-4113-4931-A9C3-A343E20C4BB0Q35111496-660BFB03-996B-4ADE-8117-AF7A5114B04EQ35116512-3CD1D5A6-312A-49B0-9EBE-2ED463793D64Q35135852-734AED6C-C526-4135-827D-6D252C2D6DBBQ35204942-4B4C2EB7-A101-4413-8765-9AFDA35D99E2Q36047672-D9E3F8F2-641E-4CEE-83E8-ED2CAAA13833Q36060147-799706F0-1D26-48B0-AC6A-AC110C9FE7C7Q36141930-316F6E0B-E284-4B3E-AAD7-1378DA99224DQ36484993-9940119C-5EA2-486B-8960-FD576E20F5A3Q36573521-CDD665D7-32FF-49E6-98D1-7DA473CDF6DAQ36676694-C219A3B6-AD7E-402B-B3B9-5416CA694FEBQ36802971-5B5E9248-E8A4-4E7E-8744-E7B0EDACC7C5Q36805845-6F568936-8177-4729-8E0F-0C1F90E00404Q36841959-9D4C0D19-28BA-44DB-A9C2-47A251F68600Q36947677-847C93BB-4B58-4BA4-AE0B-EF27ABD0E75FQ37022618-B8D312E5-B5CD-4A3B-BA6A-EC5F88B87E03Q37090758-33BD7B4E-AC01-466E-99AC-B7F2944E83CBQ37194881-B3A91A80-6897-4297-8D6E-690A4CB1EC70Q37304566-5BE91E85-D9DD-4894-B340-5DB52753537CQ37390051-2A7CCE92-ADCD-4D3E-87A5-A90A85DFBF96
P2860
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
@en
type
label
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
@en
prefLabel
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
@en
P2093
P50
P356
P1476
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
@en
P2093
Alexander Parkhomenko
Anthony J Dalby
Assen R Goudev
Bela Merkely
Christian Hamm
Chuen-Den Tseng
Darren K McGuire
Deepak L Bhatt
Diego Ardissino
P304
P356
10.1056/NEJMOA1205512
P407
P50
P577
2012-08-25T00:00:00Z